WuXi Biologics Wins SCRIP Award for "Best Company in an Emerging Market"
SHANGHAI and LONDON, Dec. 6, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company that offers end-to-end solutions for biologics discovery, development and manufacturing, today announced that it has won the SCRIP Award in the category o...
WuXi Biologics Commenced Construction of the Largest Biomanufacturing Facility Using Single-Use Bioreactors in Ireland
SHANGHAI and DUNDALK, Ireland, Dec. 5, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that the construction of new biologics dru...
WuXi Biologics Selected as Forbes Asia's Best Under A Billion 2018
SHANGHAI and TOKYO, Nov. 29, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it has been selected as Forbes Asia'sBest Under...
WuXi Biologics and ABL Bio Enter an Exclusive Development and Clinical Manufacturing Partnership for Multiple Bispecific Antibodies
SHANGHAI and SEOUL, Nov. 28, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK, WuXi Bio), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and ABL Bio Corporation (ABL Bio), a privately-held South ...
WuXi Biologics Commenced Construction of 1.6 million sq. ft. Biologics Innovation Center in Shanghai
SHANGHAI, Nov. 22, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that construction of a global innovation center has commenced ...
WuXi Biologics' Chief Executive Officer Dr. Chris Chen to Serve on Board of Directors at ISPE and Delivered Keynote Speech at 2018 Annual Meeting
SHANGHAI, Nov. 7, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced Dr.Chris Chen, Chief Executive Officer of WuXi Biologics, has b...
WuXi Biologics Commenced Construction of 48,000L Biologics Commercial Manufacturing Center in Shijiazhuang
* The new Biologics Center will be one of the largest in northern China SHIJIAZHUANG, China, Oct. 31, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufac...
WuXi Biologics Congratulates Tychan on Completing Human Safety Studies for the First-in-Class Zika Virus Antibody in Record Speed
SHANGHAI, Oct. 29, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company that offers end-to-end solutions for biologics discovery, development and manufacturing, today congratulates its partner Tychan on successful completion of Phase-1 ...
CANbridge Pharmaceutical and WuXi Biologics Enter into Strategic Partnership for Rare Disease Therapeutics
BEIJING and SHANGHAI, Oct. 23, 2018 /PRNewswire/ -- CANbridge Pharmaceutical Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions inChina and other markets, and WuXi Biologics (2269. HK), a leading global open-access biologics technology ...
I-Mab Biopharma Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody(TM) Platform for Three Bispecific Antibody Programs
SHANGHAI, Sept. 26, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing and I-Mab Biopharma ("I-Mab"), a biotech company focusing exclusively on innov...
WuXi Biologics Appoints Harvard Professor David R. Liu to Scientific Advisory Board
SHANGHAI, Sept. 24, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced the appointment ofDavid R. Liu, Professor of Chemistry and Ch...
WuXi Biologics Appoints Harvard Professor David R. Liu to Scientific Advisory Board
SHANGHAI, Sept. 25, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced the appointment ofDavid R. Liu, Professor of Chemistry and Ch...
WuXi Biologics' Chief Quality Officer Received Foreign Post Service Award from FDA
SHANGHAI, Sept. 18, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that Dr. Chiang Syin, Chief Quality Officer of WuXi Biologics...
WuXi Biologics and Inhibrx Enter an Exclusive Partnership for GMP Manufacturing
SHANGHAI, Sept. 11, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK, WuXi Bio), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Inhibrx, Inc. (Inhibrx), a biopharmaceutical company developing...
WuXi Biologics Selected into the Hang Seng HK 35 Index
HONG KONG, Aug. 29, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that the company has been selected by Hang Seng Indexes as a consti...
WuXi Biologics Reports Robust 2018 Interim Results
Revenue up 61.2% to a Record High of RMB1,054.4 Million Net Profit 270.7% of Same Period Last Year to RMB249.6 Million Diluted EPS 211.1% of Same Period Last Year *** Commenced Commercial Production of "Trogarzo™" Total Integrated Projects Increased to 187 Including 10 Late-Phase Projects Phe...
WuXi Biologics Commenced Process Validation in MFG2
* Produced 7 batches at 6,000L/12,000L bioreactor scale for three programs, the largest scale cell culture operations inChina at 100% success rate in MFG2, the largest biologics manufacturing facility globally leveraging single-use technology * Process validation in MFG2 is a key milestone of...
WuXi Biologics Announced Successful Completion of the First cGMP Run in MFG3
- One of the largest biologics clinical manufacturing facilities globally with 6 production lines which enable WuXi Biologics to complete 60 IND-enabling projects per year SHANGHAI, July 25, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK, WuXi Bio), a leading global open-access biologics te...
WuXi Biologics and Immune Pharmaceuticals Announce Late-Phase Development and Manufacturing Partnership for a First-In-Class Monoclonal Antibody
SHANGHAI and ENGLEWOOD CLIFFS, N.J., July 9, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Immune Pharmaceuticals (Nasdaq: IMNP) ("Immune")...
WuXi Biologics and Harbour BioMed Announce Strategic Development and Manufacturing Partnership
WuXi Biologics' first collaborative project based on novel fully human antibody platform - HCAb ("heavy chain only" antibodies) SHANGHAI and CAMBRIDGE, Mass., June 25, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-t...
